BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21046564)

  • 1. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease.
    Jeynes B; Provias J
    J Neurosci Res; 2011 Jan; 89(1):22-8. PubMed ID: 21046564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearing amyloid through the blood-brain barrier.
    Zlokovic BV
    J Neurochem; 2004 May; 89(4):807-11. PubMed ID: 15140180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
    Donahue JE; Johanson CE
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk.
    Takechi R; Galloway S; Pallebage-Gamarallage MM; Lam V; Mamo JC
    Prog Lipid Res; 2010 Apr; 49(2):159-70. PubMed ID: 19896503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of Alzheimer's Abeta peptide: the many roads to perdition.
    Tanzi RE; Moir RD; Wagner SL
    Neuron; 2004 Sep; 43(5):605-8. PubMed ID: 15339642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.
    Bates KA; Verdile G; Li QX; Ames D; Hudson P; Masters CL; Martins RN
    Mol Psychiatry; 2009 May; 14(5):469-86. PubMed ID: 18794889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
    Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunity in brain aging and Alzheimer's disease.
    Bouras C; Riederer BM; Kövari E; Hof PR; Giannakopoulos P
    Brain Res Brain Res Rev; 2005 Jun; 48(3):477-87. PubMed ID: 15914253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease?
    Pluta R
    Neurol Res; 2006 Sep; 28(6):665-71. PubMed ID: 16945220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison.
    Jeynes B; Provias J
    Acta Neuropathol; 2006 Oct; 112(4):417-27. PubMed ID: 16830133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier alterations in ageing and dementia.
    Popescu BO; Toescu EC; Popescu LM; Bajenaru O; Muresanu DF; Schultzberg M; Bogdanovic N
    J Neurol Sci; 2009 Aug; 283(1-2):99-106. PubMed ID: 19264328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
    Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
    J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42).
    Sultana R; Perluigi M; Butterfield DA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 833(1):3-11. PubMed ID: 16236561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.